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Background & objectives: Drug efflux pumps have been contributing factor(s) in the development of 
multidrug resistance in various clinically relevant bacteria. During efflux pump gene expression studies 
on mycobacteria, we have found a previously uncharacterized open reading frame (ORF) Rv2459 to be 
overexpressed in drug stressed conditions. The objective of the present study was to investigate the role 
of this ORF as a drug efflux pump, which might add new information in our understanding about the 
alternative mechanisms of drug resistance in mycobacteria.
Methods: The open reading frame Rv2459 of Mycobacterium tuberculosis encoding a probable drug 
efflux protein has been cloned using pSD5 E.coli-Mycobacterium shuttle vector and overexpressed in M. 
tuberculosis H37Rv. This ORF was named as jefA. Overexpression of this gene in clones has been verified by 
real-time reverse transcription PCR. Minimum inhibitory concentrations (MICs) of recombinant as well 
as non-recombinant clones were determined by resazurin microtitre assay plate method (REMA) with and 
without efflux pump inhibitors carbonyl cyanide m-chlorophenylhydrazone (CCCP) and verapamil. 
Results: In recombinant strains of M. tuberculosis, the overexpression of this gene led to an increase in 
MIC of anti-tubercular drugs isoniazid and ethambutol when tested by REMA. In the presence of CCCP 
and verapamil, the recombinant strains showed decrease in MIC for these drugs. Bioinformatic analysis 
has shown a close relation of JefA protein with drug efflux pumps of other clinically relevant bacteria. 
In homology derived structure prepared from nearest available model, it was observed that amino acids 
forming TMH 1, 8 and 11 participated in ethambutol specificity and those forming TMH 2, 7 and 10 
participated in isoniazid specificity in JefA.
Interpretation & conclusion: The increased transcription of jefA leads to increased resistance to 
ethambutol and isoniazid in M. tuberculosis via efflux pump like mechanism and contributes in the 
development of resistance to these drugs. JefA amino acid sequence is well conserved among clinically 
important bacterial genera, which further provides evidence of being a potent drug efflux pump. The 
involvement in drug resistance and very little homology with any of the human proteins makes JefA 
important to be included in the list of potential drug targets.
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 Efflux pump mediated multidrug resistance 
has become a significant complicating factor in the 
chemotherapy of bacterial infections. Efflux pumps are 
plasma membrane proteins having ability to extrude 
various antimicrobial substances outside the cell by 
an energy dependent manner. The main function of 
these efflux pumps is to extrude out environmental 
toxic substances entering the cell wall as well as 
metabolic wastes of the cell, thus providing protection 
to the cell from the toxic effect of these substances1. 
It is thought that these pumps arose so that noxious 
substances could be transported out of the bacterium 
allowing its survival, and their increased expression is 
associated with resistance to alien substances including 
drugs. These pumps are often called multidrug efflux 
pumps2. On the basis of bioenergetics and structural 
criteria multidrug efflux pumps are divided into two 
major classes. Secondary multidrug transporters utilize 
the trans-membrane electrochemical gradient of proton 
or sodium ion to drive the extrusion of drugs from the 
cell. These include transporters of major facilitator 
superfamily (MFS), small multidrug resistance family 
(SMR), resistance nodulation division family (RND) 
and multidrug and toxic compound extrusion family 
(MATE). On the other hand, ABC (ATP binding 
cassette) type multidrug transporters use the free energy 
of ATP hydrolysis to pump drugs out of the cell3. Though 
p-glycoprotein (P-gp) discovered by Juliano and Ling4 
is the most studied and characterized efflux pump in 
eukaryotes, involved in resistance to anticancer drugs5, 
a number of efflux pumps have also been identified 
and characterized in bacteria, especially in Escherichia 
coli, Pseudomonas aeruginosa, Bacillus subtilis, 
Staphylococcus aureus, etc6. In tuberculosis, responses 
to chemotherapy have been greatly challenged by 
the increasing drug resistance. Multidrug resistance 
(MDR, resistance to at least isoniazid and rifampicin) 
has grown up into its more deadly form, extensive 
drug resistance (XDR), in which Mycobacterium 
tuberculosis isolates are resistant to isoniazid and 
rifampicin as well as any fluoroquinolone and at least 
one of three injectable second-line drugs i.e., amikacin, 
kanamycin, or capreomycin7. Mutations in the genes 
associated with the mode of action of the drugs have 
been considered as the main mechanism for drug 
resistance in M. tuberculosis. Alternative mechanisms 
such as decreased cell wall permeability to drugs 
and active efflux pumping are likely to be important 
for several drugs specially in isolates in which no 
mutation in target genes are found. M. tuberculosis, 
being the causative agent of tuberculosis, has been 
studied for the presence and activity of a number of 
efflux pump genes and their encoded products8-17. 
One of the open reading frames (ORF) in the genome 
sequence of M. tuberculosis, Rv2459, annotated as 
gene encoding probable drug efflux protein (Welcome 
Trust Sanger Institute, http://www.sanger.ac.uk/
Projects/M_tuberculosis/Gene_list/functional_classes/
III.A.6.shtml), was studied in the present work. In our 
earlier microarray and real-time PCR based studies, 
this gene has been identified to be overexpressed in 
isoniazid and ethambutol induced cultures of multidrug 
resistant M. tuberculosis18 (Indian Patent application 
No. 2071/DEL/2007) and we have named it as jefA. 
We further investigated the phenotypic effect of jefA 
overexpression in H37Rv in order to know its role in 
conferring resistance to common anti-tubercular drugs 
in M. tuberculosis.
Material & Methods
Bacterial strains, plasmids, media and reagents: 
Reference strain M. tuberculosis H37Rv (TMC 102) 
was obtained from Mycobacterial Repository Centre 
at National JALMA Institute for Leprosy & Other 
Mycobacterial Diseases, Agra. Competent cells of 
H37Rv, E. coli XL1Blue19 and replicative plasmid 
pSD520 were obtained from stocks earlier prepared 
by Dr A.K. Tyagi. For growth of M. tuberculosis, 
MiddleBrook 7H9 broth with ADC supplement (7H9-S) 
and 7H11 agar with OADC supplement (7H11-S; 
Difco, USA) were used. Luria Bertani (LB) medium 
was used for culturing E. coli. Resazurin sodium salt 
powder was obtained from Sigma, USA.
Antibiotics and inhibitors: Rifampicin, isoniazid, 
ethambutol, streptomycin, ofloxacin, norfloxacin, 
kanamycin and efflux pump inhibitors carbonyl cyanide 
m-chlorophenylhydrazone (CCCP) and verapamil 
were obtained from Sigma, USA. Rifampicin and 
CCCP were dissolved in dimethyl sulphoxide (DMSO, 
Sigma, USA), while rest of the drugs were dissolved 
in distilled water (D/w; Span Diagnostics, India). All 
drugs and inhibitors were filter sterilized through 0.22 
µm filters (Millipore, USA).
Primer designing and amplification of Rv2459 (jefA): 
Forward and reverse primers (TBc1-F & TBc1-R) 
for whole gene amplification were designed using 
DNA sequence of Rv2459 taken from Tuberculist 
web server (http://genolist.pasteur.fr/TubercuList/). 
Primers were flanked with recognition sequences of 
restriction enzymes NdeI and MluI at their 5’ end with 
six additional base pairs at extreme 5’ end in both the 
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primers. PCR was set up in a 25 µl reaction volume 
for amplification of whole gene with 1X CERTAMP 
buffer, 1.5 units of CERTAMP enzyme (BioTools, 
Spain), 800 µM dNTP mix (Bangalore Genei, India), 
3 mM MgCl2 (Bioron GmbH, Germany), 1.5 µM each 
of forward and reverse primers and 2 µl H37Rv DNA 
(boiled and snap chilled). The cycle parameters of 
PCR included initial denaturation at 94oC for 5 min 
followed by 35 cycles of 94oC for 1 min, 60oC for 30 
sec and 72oC for 2 min, followed by a final extension 
of 5 min at 72oC. This resulted in an amplification 
of 1551 bp (1527 bp Rv2459 + 12 bp sequence of 
recognition sites of restriction enzymes NdeI and MluI 
+ 12 extra bp, 6 each at 5’ end of both the primers). The 
sequences of primers are given in Table I. Primers for 
detection of jefA (Rv2459-F and Rv2459-R) and that 
of polA (polA-F and polA-R) were designed by using 
free online software Primer3 with default parameters21. 
The 1551 bp amplified PCR product (insert) having 
flanking restriction sequences was run on agarose 
gel electrophoresis and eluted from the gel by using 
QIAGEN kit (QIAGEN GmbH, Germany) or GFX 
DNA purification kit (Amersham Pharmacia, UK). 
Insert and vector pSD5, both were double digested with 
restriction enzymes NdeI and MluI (MBI Fermentas, 
USA). For restriction digestion, 1 µg of DNA was 
digested with 10 units of MluI and 20 units of NdeI 
and incubated at 37oC for 3-4 h. Restricted insert and 
vector were ligated by using 4 units of T4 DNA ligase 
(Bangalore Genei, India) with overnight ligation at 
22oC. Ligation was also performed using Quick Ligase 
(New England Biolabs, UK) at room temperature for 
10 min.
Transformation in E. coli: Ligation mixture was 
subjected to transformation in E.coli XL1Blue cells 
(efficiency 107 cfu/µg) by heat shock treatment and 
streaked on LB agar plates with kanamycin (25 µg/
ml) and incubated at 37oC overnight. Single colonies 
thus obtained were inoculated in 5 ml LB broth with 
kanamycin (25 µg/ml) and incubated at 37oC overnight. 
Plasmid DNA from overnight culture of E. coli was 
isolated by alkaline lysis method with TEG (25 mM 
Tris-Cl pH 8, 10 mM EDTA, 50 mM glucose), NaOH 
and potassium acetate. Recombinant plasmids were 
verified by sequencing, restriction digestion with MluI 
and NdeI and further verified by PCR amplification of 
whole gene of jefA from plasmid DNA isolated from 
E. coli cells.
Electroporation in M. tuberculosis: Plasmid DNA (100 
ng) containing jefA gene (pSD5-jefA) was mixed with 
25 µl of electrocompetent cells of H37Rv (efficiency 
104 cfu/µg). Electroporation was done in a Cell Porator 
(Gibco BRL, USA) at 330 µF, 8 KΩ and 375 volts. 
Cells were revived in 1 ml 7H9 medium at 37oC for 
24 h and then streaked on 7H11 plates with kanamycin 
(25µg/ml), alongwith plates streaked with H37Rv as 
negative control, and incubated for 25 days at 37oC. 
Cells were also electroporated with only plasmid DNA 
(pSD5) as expression control. Colonies obtained were 
grown on 7H11 medium plates with kanamycin and 
adapted in 7H9 broth with kanamycin for 7 days at 
37oC in a shaker incubator at 200 rpm. Growth was 
stored in 1 ml aliquots for further use. Recombinant 
clones were verified by sequencing.
RNA isolation: RNA from M. tuberculosis cultures 
were isolated by TRI Reagent (Sigma, USA). Briefly, 
two loopful of growth in 400 µl D/w was incubated 
with 100 µl lysozyme (20 mg/ml, Sigma, USA) for 
15 min at 37oC. TRI Reagent (800 µl) was added and 
incubated at room temperature for 5 min. Suspension 
was passed through 1 ml (26 gauge) syringe needle 
5 times and centrifuged at 12,000 g for 5 min. 
Deproteinization was done with 200 µl chloroform 
followed by centrifugation at 6000 g for 5 min. Upper 
aqueous layer was collected and RNA was precipitated 
with 0.75 per cent isopropanol and washed with 150 
µl of 75 per cent ethanol with centrifugation at 10,000 
g for 15 min. Pellet was air-dried and resuspended in 
30 µl of diethyl pyrocarbonate (DEPC, Sigma, USA) 
treated D/w. RNAs were treated with DNaseI enzyme 
(1U/10 µl of RNA, Ambion, USA) prior to real-time 
RT-PCR.
Real-Time RT-PCR: Overexpression of jefA in 
recombinant H37Rv was confirmed by real-time 
reverse transcription PCR in a Light Cycler using RNA 
Amplification SYBR Green I kit (Roche Diagnostics, 
Germany) using the protocols of the manufacturer. 
For real-time RT-PCR, primers used were same as 
described in Table I (Rv2459 F & R and polA F & 
R). The annealing temperatures of both the primers 
were 60oC. The starting amounts of RNAs for jefA and 
polA amplifications were equalized for each sample. 
The crossing point (CP) values of jefA amplification 
were recorded for each sample i.e., clones harbouring 
recombinant plasmid pSD5 containing jefA gene 
(H37Rv-pSD5-jefA), clones harbouring only plasmid 
pSD5 with no jefA insert (H37Rv-pSD5) and reference 
strain H37Rv. Mean ΔCP values were calculated and 
normalized to that of a housekeeping gene polA by 
2-ΔΔCt method22. Relative quantification was done to 
determine over-expression of jefA gene in H37Rv-
pSD5-jefA as compared to that of H37Rv-pSD5. ΔCP 
values were also calculated and normalized for clones 
and reference strain H37Rv.
MIC determination by REMA: MICs of H37Rv-pSD5-
jefA, H37Rv-pSD5 and of H37Rv were determined by 
Resazurin microtitre assay (REMA) plate method23-26 
with concentrations of drugs ranging from 0.125 to 
16 µg/ml. MICs of the clones were also determined 
in the presence of efflux pump inhibitors CCCP (0.5 
µg/ml), verapamil (5 µg/ml) and CCCP + verapamil. 
The concentrations of the inhibitors were decided after 
studying the effect of concentration dependent titration 
performed with these inhibitors on H37Rv. Briefly, 
100 µl 7H9-S medium was dropped in every well 
of 96-well microtitre plates (only medium, medium 
with CCCP, medium with verapamil and medium 
with CCCP + verapamil in separate rows) except 
peripheral wells where 250 µl D/w was dropped to 
prevent evaporation during incubation. Two-fold serial 
dilutions of drugs were made directly into the wells. 
100 µl mycobacterial inoculum of turbidity resembling 
0.1 MacFarland index were added to each well except 
peripheral wells containing D/w. Medium control 
(only medium without drug, inhibitor and inoculum), 
growth control (medium without drug and inhibitor 
but with inoculum) and inhibitor controls (medium 
without drug but with inhibitor/s and inoculum) were 
also made in each plate. Plates were covered and 
incubated for 7 days at 37oC. After 7 days 30 µl of 0.02 
per cent resazurin sodium salt solution was added to 
each well and again incubated for further 24 h at 37oC. 
A change in colour of the resazurin dye from blue to 
pink was considered as positive growth and MIC was 
determined as corresponding concentration in the first 
blue colour in a row. All the experiments were repeated 
at least three times.
Phylogenetic and structural analysis: Distance 
relationship of JefA with homologous sequences within 
mycobacterial species, other organisms and human 
was studied. Protein sequence of JefA was derived 
from TubercuList web server (http://genolist.pasteur.
fr/TubercuList/) and BLASTp was performed through 
NCBI server27. Multiple sequence alignment was done 
using ClustalW28 with the related sequences obtained 
from BLASTp. Phenograms for distance relation 
analysis within mycobacterial species as well as within 
other organisms were generated using free online 
programme Phylodendron (© 1997 by DG Gilbert) as 
well as by NCBI web server using Neighbour-Joining 
Table I. Bacterial strains, plasmids and oligos used in this study
Strains / Plasmids Description Source/Reference
Strains :
XL1Blue E. coli strain recA1 endA1 gyrA96 thi-1 hsdR17 supE44 Bullock et al, 198719
XL1Blue-pSD5-jefA XL1Blue harbouring pSD5-jefA Present study
H37Rv M.tuberculosis reference laboratory strain Mycobacterial 
Repository Centre, 
NJIL&OMD, Agra
H37Rv-pSD5 H37Rv harbouring pSD5 vector Present study
H37Rv-pSD5-jefA H37Rv harbouring pSD5-jefA Present study
Plasmids:
pSD5 E. coli-mycobacterium shuttle vector with mycobacterial hsp60 DasGupta et al, 199820
promoter, Knr, oriM, pl5A
pSD5-jefA pSD5 vector containing jefA gene in its multiple cloning site Present study
Oligos:
TBc1 (F) 5’>GAATTACATATGTCCCACACTGCAA TGACACCG<3’ Present study
TBc-1 (R) 5’>GAATTTACGCGTTTAGCTGGCGGGG GTCCGG<3’ Present study
Rv2459 (F) 5’>TGGACGTCAACATCGTCAAT<3’ Present study
Rv2459 (R) 5’>GTGACCCCGAACACAAAACT<3’ Present study
PolA (F) 5’> TTTCACTGCTCGATGACGAC<3’ Present study
PolA (R) 5’> TACCGGCACTTTCCATCTTC<3’ Present study
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method. Trans-membrane regions in JefA protein were 
predicted by TMpred29 and TMHMM server version 
2.0 (http://www.cbs.dtu.dk/services/TMHMM/).
Results
Real-time RT-PCR analysis of clones: Real-time 
reverse transcription PCR using SYBR Green 
I format confirmed over-expression of jefA in 
M. tuberculosis H37Rv containing recombinant vector 
(H37Rv-pSD5-jefA) with respect to H37Rv containing only 
pSD5 vector (H37Rv-pSD5) as well as reference strain M. 
tuberculosis H37Rv. A greater than 16 fold overexpression 
of jefA has been detected by real-time RT-PCR in clones 
with recombinant vectors as compared to those with 
non-recombinant vectors by the 2-∆∆Ct method22. CP and 
ΔCP values in each case are shown in Table II. Relative 
normalized value ΔΔCP for recombinant and non-
recombinant clones was >4, while that of recombinant 
clones and H37Rv was >3, showing a greater than 16 fold 
over-expression of jefA gene in recombinant clones.
MIC determination of clones by REMA and effect of 
efflux pump inhibitors: There was no significant change 
in MICs of rifampicin, ofloxacin and norfloxacin 
in clones. However, in the case of other three drugs 
(ethambutol, isoniazid and streptomycin), the levels 
of resistance increased in jefA overexpressing clones. 
Whereas MIC of streptomycin was found increased 
by 8-fold only (from 0.125 to 1 µg/ml), MICs of 
isoniazid and ethambutol showed an increase of 64-
fold (from 0.125 to 8 µg/ml) and 16 fold (0.5 to 8 
µg/ml) respectively (Table III). When efflux pump 
inhibitors CCCP, verapamil and a combination of 
CCCP and verapamil were used in parallel wells in 
REMA, MICs showed a decrease in the case of these 
three drugs. CCCP lowered the MIC of streptomycin by 
2-fold whereas verapamil singly as well as with CCCP 
lowered the MIC by 4-fold. While MIC of isoniazid 
was not lowered by verapamil, CCCP lowered the MIC 
by 2-fold. In case of ethambutol, CCCP lowered its 
MIC by 8 fold (from 8 to 1 µg/ml), which was greater 
than the decrease effected by verapamil (from 8 to 4 
µg/ml). However, slight increase in MIC of rifampicin 
(from 0.125 to 0.25 µg/ml) was not decreased with 
pump inhibitors and therefore this increase was not 
considered as effect of efflux pump.
Phylogenetic analysis: Homology search and multiple 
sequence alignment of JefA with other bacterial 
sequences showed presence of close homologous 
regions (Fig. 1), whereas with human proteins showed 
very little identity i.e. <27 per cent with any of the 
human protein (Table IV) with rarer alignments 
(Fig. 2). It is evident from the phylogenetic tree drawn 
Table III. MIC of anti-tubercular drugs in bacterial strains 
harbouring foreign DNA
Drugs MIC (μg/ml)
H37Rv H37Rv- 
pSD5
H37Rv- 
pSD5-jefA
RIF <0.125 <0.125 0.25
RIF+CCCP <0.125 <0.125 0.25
RIF+VER <0.125 <0.125 0.25
RIF+CCCP+VER <0.125 <0.125 0.25
INH <0.125 <0.125 8
INH+CCCP <0.125 <0.125 4
INH+VER <0.125 <0.125 8
INH+CCCP+VER <0.125 <0.125 4
EMB 0.5 0.5 8
EMB+CCCP 0.5 0.5 1
EMB+VER 0.5 0.5 4
EMB+CCCP+VER 0.5 0.5 1
STR 0.25 <0.125 1
STR+CCCP 0.25 <0.125 0.5
STR+VER 0.25 <0.125 0.25
STR+CCCP+VER 0.25 <0.125 0.25
OFL 0.25 0.25 0.25
OFL+CCCP 0.25 0.25 0.25
OFL+VER 0.25 0.25 0.25
OFL+CCCP+VER 0.25 0.25 0.25
NOR 0.25 0.25 0.25
NOR+CCCP 0.25 0.25 0.25
NOR+VER 0.25 0.25 0.25
NOR+CCCP+VER 0.25 0.25 0.25
RIF, rifampicin; INH, isoniazid; EMB, ethambutol; STR, 
streptomycin; OFL, ofloxacin; NOR, norfloxacin; CCCP, carbonyl 
cyanide m-chlorophenylhydrazone; MIC, minimum inhibitory 
concentration; VER, verapamil
Table II. Overexpression of jefa gene in recombinant clones as 
determined by real-time
gene Crossing points (CP) values
Mean CP
(Cl # jefA)a
Mean CP
(Cl # pSD5)b
Mean CP
(H37Rv)c
ΔCP (jefA &
pSD5)
ΔCP (jefA
& Rv)
(A) (B) (C) (B)– (A) (C) – (A)
jefA 19.18 24.62 25.55 5.44 6.37
polA 19.49 20.25 22.58 0.76 3.09
Relative normalized difference in expression
(ΔΔCP)
4.68 3.28
aClones containing recombinant vector (H37Rv-pSD5-jefA); bClones
containing non-recombinant vector (H37Rv-pSD5); cReference strain
H37Rv. polA was used as reference gene
180 INDIAN J MED RES, AUGUST 2010
Fig. 1. Multiple sequence alignment of JefA with homologous bacterial proteins found with maximum identities. Block shows the sequence 
of M. tuberculosis forming major facilitator superfamily motif. Bold letters show amino acids forming transmembrane segments.
 GUPTA et al: JEFA & ANTI-TB DRUG RESISTANCE IN M. TUBERCULOSIS 181
Fig. 2. Multiple sequence alignment of JefA with human proteins found with maximum identities. Very little identities can be seen within 
sequences as dots and asterisks. JefA: M. tuberculosis JefA, Vesicular: vesicular acetylcholine transporter (Homo sapiens), Sodium: sodium 
phosphate (Homo sapiens), Facilitated: facilitated glucose transporter (Homo sapiens), Inorganic: sodium-dependent inorganic phosphate 
cotransporter (Homo sapiens), SLC17A8: SLC17A8 protein (Homo sapiens). 
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within mycobacterial species that the amino acid sequence 
of JefA is well conserved in M. tuberculosis and M. bovis. 
Other mycobacterial species showing close relation 
to JefA sequence are M. ulcerans and M. vanbaalenii 
(Fig. 3a). Among other organisms, Salinospora, 
Streptomyces, Verminephrovector, Frankia and Serratia 
are the genera showing closely related homologues of JefA 
but distant than mycobacterium (Fig. 3b). All homologues 
are membrane drug transport/efflux proteins suggesting 
a common structural and functional behaviour of these 
sequences. Transmembrane region prediction analysis 
showed that it is a protein with 14 transmembrane helices 
(TMH) suggesting its location as a transmembrane protein 
in the cell (Fig. 4a). Due to unavailability of a modeled 
template with significant amino acid identity (>40%), 
structure of JefA could not be completely understood. 
However, homology derived structure prepared from 
nearest available model (Fig. 4b), suggests that amino 
acids, forming TMH 1, 8 and 11, participate in ethambutol 
specificity and those forming TMH 2, 7 and 10 participate 
in isoniazid specificity in JefA.
Discussion
 Multidrug resistance in tuberculosis has become an 
increasing threat around the world. Various important 
antitubercular drugs like streptomycin, rifampicin, 
isoniazid, ethambutol and fluoroquinolones have 
become therapeutically ineffective in a section of 
cases due to development of multidrug resistance. 
This multidrug resistance is also important in the 
case of non-tuberculous mycobacteria (NTM), which 
are naturally resistant to a number of therapeutically 
relevant anti-tubercular drugs.
 Mycobacterial drug efflux pumps have been known 
since the identification of LfrA in M. smegmatis30,31. 
Since its discovery, a number of genes have been 
identified and characterized in mycobacterial species. 
These genes have been shown to increase the MICs 
of antibacterial substances when overexpressed in a 
suitable host8,10,14. Several genes which are thought to 
encode efflux pump proteins are still unexplored. The 
ORF, Rv2459, which has been characterized in this 
Fig. 3a. Phylogenetic tree showing distance relationship analysis of JefA within mycobacterial species.
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study, has been described in M. tuberculosis database 
as ‘probable conserved integral membrane transport 
protein’ (http://genolist.pasteur.fr/TubercuList/). After 
detecting its overexpression in multidrug resistant 
isolates of M. tuberculosis in our microarray and real-
time PCR based studies18 (Indian Patent application 
No. 2071/DEL/2007), it has been designated as ‘jefA’. 
In the present work, this gene has been amplified from 
standard laboratory strain M. tuberculosis H37Rv, 
subcloned in E. coli, and finally cloned in H37Rv itself 
through a mycobacteria-E. coli expression shuttle 
vector pSD520 to make it overexpress its phenotype. 
Cloned H37Rv cells showed >16 fold increased 
expression of jefA as confirmed by real-time RT-
PCR analysis. A comparison of MICs of drugs in 
recombinant versus non-recombinant clones by REMA 
showed that MICs for isoniazid and ethambutol were 
increased significantly (16 to 64 fold) in recombinant 
clones followed by, to a relatively lesser amount, that 
of streptomycin. An increase in MICs of isoniazid 
and ethambutol suggests that jefA is actively involved 
in extrusion of these drugs. This also reconfirms the 
results published with multidrug resistant isolates18. 
Experiments with protonophore CCCP and calcium 
channel blocker verapamil, singly or together, indicated 
that active efflux of these drugs from the bacterial 
cell was responsible for the increase in their MICs. 
The blocking effect of CCCP and verapamil brought 
down, although not fully, the increase in isoniazid and 
ethambutol MICs. The decrease in MIC of ethambutol 
by CCCP was greater than that for isoniazid. It may be 
presumed that the concentration of CCCP required to 
Fig. 3b. Phylogenetic tree showing distance relationship analysis of JefA within other organisms.
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lower isoniazid MIC should be greater than what was 
taken. However, increasing the CCCP concentration 
can rather affect the natural growth of the bacteria 
as observed in our parallel experiments to determine 
the optimum concentration of the inhibitors after 
performing concentration dependent titration of the 
wild type bacterial growth (data not shown). On the 
other hand, verapamil showed only little effect in both 
the cases. Inclusion of reserpine could also have added 
some information about decrease in MIC of drugs in 
jefA clones, which may be similar or little different. 
Small decrease in the MIC of streptomycin by both 
the inhibitors in the clones, compared to other drugs, 
suggests a mild involvement of jefA in streptomycin 
resistance. Moreover, the greater effect of verapamil 
on streptomycin MIC than that by CCCP suggests 
possible involvement of another ABC family pump 
in streptomycin resistance. Although no increase was 
found in the MICs of fluoroquinolones- ofloxacin 
and norfloxacin in the present study, these drugs are 
assumed to be potential targets for efflux mediated 
resistance30-32. As the drugs tested in the present study 
are used commonly in anti-TB therapy, we have 
concerned on clinically relevant drugs and not included 
other synthetic compounds in the study which may be 
possible efflux pumps substrates.
 When JefA protein sequence was searched in 
databases for its homologous sequences, 39, 35 
Fig. 4. Analysis of JefA protein structure. (a) Transmenbrane helix 
prediction of JefA protein by TMHMM server showing 14 trans 
membrane helices, (b) Homology derived model of JefA prepared 
using Swiss-model.
Table IV. Organisms, which show maximum homology with amino 
acid sequence of JefA
Identity within proteomes
Protein description Organism Identity 
(%)
Mycobacteria:
Putative integral membrane 
transport protein
M. bovis BCG pasteur 100
Putative transmembrane 
transport protein
M. tuberculosis H37Ra 100
Probable conserved 
membrane transport protein
M. bovis 99
Conserved integral 
membrane transport protein
M. ulcerans 77
Drug resistance transporter, 
EmrB/QacA
M. vanbaalenii 30
Other bacteria:
Drug resistance transporter, 
EmrB/QacA
Salinispora arenicola 39
Putative efflux membrane 
protein
Streptomyces 
avermitilis
36
Drug resistance transporter, 
EmrB/QacA
Verminephovector 
eiseniae
35
Drug resistance transporter 
EmrB/QacA
Frankia species 34
Major facilitator superfamily 
MFS_1
Serratia 
proteamaculans
34
Human:
Vesicular acetylcholine 
transporter (VAChT)
Homo sapiens 27
solute carrier family 17 
(sodium phosphate)
Homo sapiens 25
solute carrier family 
2 (facilitated glucose 
transporter)
Homo sapiens 23
sodium-dependent inorganic 
phosphate cotransporter
Homo sapiens 21
SLC17A8 protein Homo sapiens 21
(a)
(b)
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and 34 per cent amino acid identity was found with 
QacA family drug transporter proteins of Salinispora 
arenicola, Verminephovector eiseniae and Frankia 
species respectively. This suggests that JefA is closely 
related to drug transport proteins. Phylogenetic 
relationship of JefA showed that within mycobacterial 
species its amino acid sequence is well conserved 
especially within M. ulcerans and M. bovis. Relation of 
JefA with its homologues within other organisms shows 
that JefA amino acid sequence is conserved within high 
GC Gram positive organisms. The homology of JefA 
with membrane efflux proteins of other bacteria as 
well as its transmembrane region analysis indicated the 
nature and location of JefA as a transmembrane efflux 
pump containing 14 TMH. Although specificity of 
most of these sequences particularly for isoniazid and 
ethambutol is not known, homology in these sequences 
is suggestive of common specificity for other synthetic 
compounds, which may be the preferred substrates for 
these homologous pumps and which can be one of the 
natural defense mechanisms. Little identity of JefA with 
any of the human proteins and their rarer alignment 
suggests presence of non-homologous regions in JefA 
structure, which can be important as potential drug 
targets. 
 Although mutations in drug target genes are still 
thought to be the primary mechanism of resistance, 
they alone are unable to account for all cases of INH 
and EMB resistance in M. tuberculosis33-37. Hence, 
there is a need to look for alternative mechanisms 
such as efflux pumps in such situations. The role of 
efflux pumps in conferring INH and EMB resistance 
has been described in M. tuberculosis, where an efflux 
pump of resistance nodulation division (RND) family, 
mycobacterial membrane protein large (mmpL7), has 
been found to confer INH resistance14, and another 
gene, iniA, encoding a pump component has been 
observed to assist an efflux pump to provide resistance 
to INH and EMB13. Microarray based studies have also 
identified an efflux pump gene efpA (Rv2846c) to be 
induced by INH treatment38,39.
 Our study provides significant new information 
about efflux mechanisms contributing in INH and 
EMB resistance through a MFS family efflux pump, 
JefA, which acts as alternative/additional mechanism 
of resistance to these drugs in M. tuberculosis. The 
increase in MICs of these drugs, when jefA was cloned 
in M. tuberculosis and the decrease in their MICs by 
efflux pump inhibitors CCCP and verapamil support 
its nature as a gene encoding efflux pump of major 
facilitator superfamily, which is also indicated by the 
transmembrane region prediction analysis of JefA as 
well as by its phylogenetic analysis. It can further be 
investigated in jefA knock-out strains to reinforce the 
observations. In conclusion, our results suggest that jefA 
gene contributes in isoniazid and ethambutol resistance 
in M. tuberculosis through an efflux pump mediated 
mechanism. Its actual epidemiological significance can 
be assessed only by the study of naturally occurring 
INH and EMB resistant isolates from patients. Since 
no known structural model of a close homologue of 
JefA with a significant sequence identity (>40%) 
has been identified based on BLASTp27 and SWISS 
MODEL40 analysis, further characterization of JefA 
requires alternative bioinformatics methods, X–ray 
crystallography or NMR spectroscopy analysis of JefA 
to explain on the basis of structure-function relationship, 
why it is preferentially associated with ethambutol and 
isoniazid resistance and not with other drugs tested.
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